Mature pipeline of biopharmaceuticals for rare diseases. Government funding for biodefense business. Soligenix is a two-segment business. They have a biotherapeutics rare disease segment focused on cancer, cancer supportive care and inflammation and a separate vaccine/biodefense segment of business funded entirely by the U.S. government, focused on medical countermeasures for military and civilian use. See Soligenix’s Profile.
Author: Brett Johnson
June 7, 2019, by NCI Staff Smoldering myeloma is a slow-growing type of multiple myeloma, a form of cancer in which abnormal plasma cells (purple) make too much of a single type of antibody. The drug lenalidomide (Revlimid) may delay the development of multiple myeloma in individuals with smoldering myeloma that is at high risk of progressing to cancer, according to preliminary results from a clinical trial. Smoldering myeloma is a precancerous condition that alters certain proteins in blood and/or increases plasma cells in bone marrow, but it does not cause symptoms of disease. About half of those diagnosed with the condition, however, will develop multiple myeloma within 5 years.…
JUNE 4, 2019 NFCR WRITER DAVID PERRY BLOG Ask any parent about their child fighting cancer and words like “nightmare” and “helpless” will almost certainly be part of the conversation. Within pediatric cancer medicine, the entire field faces the brutal reality that chemotherapy, surgery and most other cancer treatments are not designed for children. This can be somewhat understandable, since cancer is predominantly an adult disease. There are more than 100 kinds of cancer, yet the American Cancer Society lists just eight as common among children. Yet pediatricians cannot, on the fly, convert adult therapies to use for child patients. Use too little of…
The latest Annual Report to the Nation on the Status of Cancer finds that, for all cancer sites combined, cancer death rates continued to decline in men, women, and children in the United States from 1999 to 2016. Overall cancer incidence rates, or rates of new cancers, decreased in men from 2008 to 2015, after increasing from 1999 to 2008, and were stable in women from 1999 to 2015. In a special section of the report, researchers looked at cancer rates and trends in adults ages 20 to 49. The annual report is a collaborative effort among the National Cancer…
Soligenix is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is currently an unmet medical need. Soligenix is a biotherapeutic business segment dedicated to the development of products for orphan diseases and areas where there are currently no drug therapies approved, such as Cutaneous T-Cell Lymphoma, oral mucositis, and pediatric Crohn’s disease. They are now conducting two Phase 3 clinical trials with multiple data reads through 2019 and early 2020. Their first Phase 3 trial, for cutaneous T-cell Lymphoma (or CTCL), used a novel photodynamic therapy for the first-line treatment of this…
New findings from a study by researchers at the National Cancer Institute (NCI), part of the National Institutes of Health, show that U.S. incidence rates for aggressive subtypes of uterine cancer rose rapidly among women ages 30 to 79 from 2000 to 2015. The findings also reveal racial disparities, including higher incidence of these aggressive subtypes and poorer survival—irrespective of subtype and cancer stage—among non-Hispanic black women than among women in other racial/ethnic groups. The study, published May 22, 2019 in the Journal of Clinical Oncology, used population data from NCI’s Surveillance, Epidemiology, and End Results (SEER) database to evaluate trends…
The Cancer Progress Report delivers crisp headlines of progress at emerging companies developing, in many cases, breakthroughs. It is a fast and efficient must read for anyone serious in the field. For companies it provides an economical means to accomplish the critical function of reaching and keeping the important informed as to progress. Editorial Content has three themes: Introductions to New Members Introduction to the company and what makes it unique. This 40 words linked to the Altru Cancer website and the company site for a full profile. Ongoing Coverage Member Progress. Update on newsworthy developments. Headline and first sentence…
A new diagnostic technology can predict how patients will respond different drugs or drug combinations before the patients take the drugs. Travera is using a breakthrough technology to measure which cancer drugs work against each individual’s unique cancer. This revolutionary diagnostic test will enable oncologists to quickly determine which drugs to prescribe based on the actual responses of their patients’ tumor cells. See Travera’s Profile.